Simplified Chinese
scroll down
20
2018-03
As the annual report season for listed companies gets underway, the 2017 financial results of several vaccine‑related firms are gradually being unveiled. Among them, Zhifei Biological, Changsheng Biological, and Kintor Pharmaceutical all posted robust growth, with their combined net profits exceeding RMB 1 billion. Zhifei Biological’s net profit surged by a factor of 12, Changsheng Biological’s net profit surpassed RMB 500 million, and Kintor Pharmaceutical saw both its revenue and net profit double. Zhifei Biological: Net Profit Soars Twelvefold According to its preliminary performance report, Zhifei Biological recorded revenue of RMB 1.343 billion in 2017, up 201.06% year over year, while its net profit reached RMB 432 million, an increase of 1,229.25% compared with the previous year.
26
2018-02
NIH client from Pakistan visits Minhai.
From January 3 to 5, 2018, clients from Pakistan’s NIH visited Minhai for a three-day training session on the formulation of measles semi‑finished products. The company was represented by Executive Deputy General Manager Liu Jiankai, Packaging Department Director Hao Yanan, Head of the International Cooperation Department Zhang Qian, and staff from Vaccine Department I, including Zhang Heping and Wang Yao.
26
2018-02
On the afternoon of December 6, 2017, Li Jianguo, Vice Chairman of the Daxing District Science and Technology Association of Beijing, along with two other members of his delegation, arrived at the company for an inspection visit. Liu Jiankai, Executive Deputy General Manager of Minhai Biotechnology, Zhu Ruibo, Deputy Director of the R&D Center, and other company leaders extended a warm welcome to the Chairman of the Daxing District Science and Technology Association on behalf of Minhai.
26
2018-02
The topping-out ceremony for Minhai’s R&D and Production Building was successfully held.
On the morning of January 15, 2018, Beijing Minhai Biotechnology Co., Ltd. held a grand topping-out ceremony for the main structure of its R&D and production building on the rooftop. The company’s Chairman Du Weimin, Executive Deputy General Manager Liu Jiankai, Deputy General Manager Yuan Liping, Quality Director Li Xiangqun, along with relevant leaders from the New Project Engineering Department and representatives from the project’s participating construction units, attended the ceremony.
26
2018-02
Minhai has signed a licensing agreement with IMUNA PHARM, A.S. regarding the mumps virus strain.
From January 8 to 10, 2018, a four-member delegation comprising the company’s General Manager Zheng Haifa, Executive Deputy General Manager Liu Jiankai, Head of the International Cooperation Department Zhang Qian, and the project leader for the mumps vaccine, Zhang Yan, paid a visit to IMUNAPHARM, A.S., located in Slovakia. Founded in 1953, IMUNAPHARM, A.S. is a Slovak pharmaceutical company whose state-of-the-art manufacturing processes and stringent quality standards meet both the requirements of the World Health Organization and the legal standards of the European Union.
Contact Information
Customer Service Hotline
4001899806
Phone number
010-59613600
Official Website
Company Address
No. 35 Simiao Road and No. 25 Tianfu Street, Daxing Biomedical Industry Base, Zhongguancun Science Park, Daxing District, Beijing
WeChat Official Account
0
%